Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company developing
potentially life-changing technologies for patients with cancer and other
serious diseases, today announced its entry into an exclusive license agreement
with the University of Pittsburgh for a diabetes gene therapy that may have the
potential to cure Type 1 and Type 2 diabetes, which together currently affect
approximately 30.3 million people in the U.S., or 9% of the U.S. population.
According to the update, Genprex’s licensed diabetes gene therapy technology is
designed to reprogram alpha cells in the pancreas into beta-like cells,
restoring their function, thereby replenishing insulin levels. “We are excited
to announce the licensing agreement with The University of Pittsburgh, and we
look forward to working with Dr. Gittes and his team to develop this
groundbreaking treatment for diabetes,” Genprex’s Chairman and Chief Executive
Officer Rodney Varner said in the news release. “At Genprex, we have always put
patient needs first, focusing on ways to bring new treatment options to patient
populations who have large unmet medical needs. We believe this diabetes gene
therapy may potentially become a new treatment option for the millions of
diabetes patients who now must take insulin replacement therapy, and it may be
effective for patients who do not benefit sufficiently from that therapy. Even
more moving, the diabetes gene therapy could hold the potential to provide long
term effectiveness, or even be a cure, for diabetes patients.”
To view the full press release, visit http://ibn.fm/Qok9p
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with cancer and
other serious diseases. Genprex’s technologies are designed to administer
disease-fighting genes to provide new treatment options for large patient
populations with cancer and other serious diseases who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to in-license and develop drug candidates to further its pipeline
of gene therapies in order to provide novel treatment approaches for patients
with cancer and other serious diseases. The company’s lead product candidate,
Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), uses
the company’s unique, proprietary platform which delivers cancer-fighting genes
by encapsulating them into nanoscale hollow spheres called nanovesicles, which
are then administered intravenously and taken up by tumor cells where they
express proteins that are missing or found in low quantities. In January 2020,
the FDA granted Fast Track Designation for Oncoprex in combination with
AstraZeneca’s Tagrisso(R) for the treatment of NSCLC. For more information,
please visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
